Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT05138458
Other study ID # MTX-TCL-101
Secondary ID
Status Suspended
Phase Phase 1/Phase 2
First received
Last updated
Start date December 15, 2021
Est. completion date October 2025

Study information

Verified date November 2023
Source Myeloid Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid cells recognize the tumor cells and are designed to target and kill them.


Description:

The research study is divided into two parts. The first part will be to determine the safety and tolerability of the study drug product. During this part of the study, there will be 4 groups of study patients. The first group of patients will receive a low dose of cells, the second group will receive the low dose of cells and lymphodepleting chemotherapy to reduce the number of T cells in the blood, the third group will receive a higher dose of cells, and the fourth group will receive the higher dose of cells and lymphodepleting chemotherapy to reduce the number of T cells in the blood. In the second part of the study, cells with or without chemotherapy will be administered based on results of Part 1 and the safety, tolerability, and efficacy of MT-101 will be assessed. All patient groups will receive 6 doses of drug product over 3 weeks.


Recruitment information / eligibility

Status Suspended
Enrollment 40
Est. completion date October 2025
Est. primary completion date November 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Adults age > or equal to18 at the time the Informed Consent is signed - Refractory or relapsed pathologically confirmed T Cell Lymphoma (TCL): Peripheral T cell Lymphoma not otherwise specified (PTCL-NOS) , Angioimmunoblastic T cell Lymphoma (AITL), ALK-negative anaplastic large cell lymphoma (ALCL), ALK-positive ALCL, or Mycosis Fungoides (MF) stage IIB-IV including large cell transformation - CD5-expressing tumor by IHC or flow cytometry of tumor biopsy within 3 months of Screening or at Screening - Eastern Cooperative Oncology Group performance status < 2 - Adequate organ function as defined in the protocol. Key Exclusion Criteria: - B1 and B2 disease (as defined in protocol for subjects with MF) - Known central nervous system involvement by PTCL - History of allogeneic transplant - History of intolerance to leukapheresis, plasmapheresis, or blood donation - Pregnant or nursing women - Any acute illness including fever (> 100.4°F or > 38°C), except fever related to tumor - Active systemic bacterial, fungal, or viral infection - Active chronic infection - Other primary malignancies, except adequately treated malignancies or complete remission - Active autoimmune disease that has required systemic therapy in the last 2 years - History of hemophagocytic lymphohistiocytosis - History of severe, immediate hypersensitivity reaction attributed to penicillin - Any other condition that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements.

Study Design


Intervention

Biological:
MT-101
CD5 ATAK cells
Other:
MT-101 + Conditioning (Lymphodepleting) Chemotherapy
IV administration of fludarabine and cyclophosphamide

Locations

Country Name City State
United States Dana-Farber/Mass General Brigham Cancer Care Boston Massachusetts
United States University of Virginia Comprehensive Cancer Center Charlottesville Virginia
United States Colorado Blood Cancer Institute Denver Colorado
United States City of Hope Comprehensive Cancer Center Duarte California
United States University of Texas MD Anderson Cancer Center Houston Texas
United States Thomas Jefferson University Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Myeloid Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Duration of response (DOR) DOR is the time interval between the date of first assessment of PR or CR to the date of the follow-on first documentation of progressive disease or death, whichever occurs earlier. 48 weeks
Other Progression free survival (PFS) PFS is defined as the time from the date of the first administration of MT-101 to the date of first documentation of progressive disease or death, whichever occurs earlier. 48 weeks
Other Overall survival (OS) OS is defined as the time from date of the first administration of MT-101 to the date of death. 48 weeks
Primary Safety and Tolerability of MT-101 Safety and tolerability of the drug will be determined based on observed adverse events (AEs), including all potential dose limiting toxicities. 4 weeks
Secondary MT-101 cell kinetics in blood The quantity of MT-101 RNA in the blood. 4 weeks
Secondary The objective response rate The ORR is defined as the number (%) of subjects achieving a best overall response of complete response (CR) or partial response (PR) 24 weeks
See also
  Status Clinical Trial Phase
Terminated NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Not yet recruiting NCT02881749 - Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides Phase 2
Completed NCT00051012 - Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Phase 4
Terminated NCT03789864 - Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides N/A
Completed NCT01590732 - Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma Phase 1
Recruiting NCT02848274 - ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Recruiting NCT00177268 - Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Recruiting NCT05357794 - Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides Phase 2
Completed NCT04955340 - A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat Phase 1
Recruiting NCT04960618 - Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome Phase 2
Completed NCT02883517 - Cell-free Circulating DNA in Primary Cutaneous Lymphomas
Active, not recruiting NCT02953301 - Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) Phase 2
Completed NCT00254332 - Effect of Denileukin Diftitox on Immune System in CTCL Patients N/A
Completed NCT02296164 - Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Recruiting NCT05680558 - Photopheresis in Early-stage Mycosis Fungoides Phase 2
Completed NCT00038376 - Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies Phase 2
Completed NCT00168064 - Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides Phase 2
Recruiting NCT05879458 - Ritlecitinib in CTCL Phase 2
Recruiting NCT05904522 - Histopathological Changes in Mycosis Fungoides N/A
Recruiting NCT05414500 - Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Phase 1